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Abstract 
Introduction: Limited data exist regarding outcomes of patients with outpatient acute 
kidney injury (AKI). To determine whether outpatient AKI is associated with increased 
mortality and chronic kidney disease (CKD), we conducted a retrospective cohort study 
utilizing an electronic health record in Minnesota.  
 
Methods: All adult patients receiving primary care through Fairview Health Services 
were included. All outpatient Cr values during an 18 month exposure period were used to 
define five comparator groups as follows: No outpatient AKI (reference group), 
outpatient AKI with recovery, outpatient AKI without recovery, outpatient AKI without 
repeat Cr, or no Cr. A Cox proportional hazard model was utilized to assess whether 
outpatient AKI was associated with an increase in mortality, CKD stage 4 and secondary 
outcomes including hospitalization and recurrent AKI. 
 
Results: The cohort consisted of 384,869 patients and 51% had at least one Cr measured 
during the exposure period. Outpatient AKI occurred in 1.4% of patients during the 18 
month exposure period and 37.8% recovered while 26.5% had no repeat Cr. Mortality 
was 3.2% over an average follow-up of 5.3 years. Outpatient AKI was associated with an 
increased risk of mortality (aHR 1.90, 95% CI 1.76-2.06) and CKD stage 4 (aHR 1.33, 
95% CI 1.11-1.59) including those that recovered from their AKI (mortality aHR 2.15, 
95% CI 1.91-2.41;  CKD aHR 1.73, 95% CI 1.37-2.19) and in those with stage 1 AKI 
(mortality aHR 1.90, 95% CI 1.74-2.07; CKD aHR 1.34, 95% CI 1.10-1.62). Outpatient 
AKI was also associated with with an increased risk of hospitalization (aHR 1.71, 95% 
CI 1.63-1.79), hospital AKI (aHR 2.14, 95% CI 1.93-2.37), and recurrent outpatient AKI 
(aHR 2.75, 95% CI 2.57-2.93). 
 
Conclusion: Outpatient AKI is common and is a risk factor for death, CKD, 
hospitalization, and recurrent AKI, including those with stage 1 AKI and those that 
recover.  
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Table 1: Characteristics and outcomes of patients overall and by AKI group 
All No AKI 
Any Outpatient 
AKI 
AKI with 
Recovery 
AKI No 
Recovery 
AKI no 
Repeat Cr No Cr 
N 384,869 190,851 5,358 2,025 1,913 1,420 188,660 
No (%) with Stage 1 AKI     4,310 (80.4)  1584 (78.2) 1,556 (81.3) 1,170 (82.4)   
No (%) with Stage 2 AKI     650 (12.1) 240 (11.9) 277 (14.5) 133 (9.4)   
No (%) with Stage 3 AKI     398 (7.4) 201 (9.9) 80 (4.2) 117 (8.2)   
Time to AKI, median (SD), days     225 (174) 180 (155) 199 (171) 364 (181)   
Baseline               
Age, mean (SD), years 45.9 (17.2) 52.5 (17.2) 60.0 (17.8) 62.1 (16.7) 61.4 (16.7) 55.1 (19.6) 38.9 (14.0) 
No (%) Male 
165,512 
(43.0) 86,325 (45.2) 165,512 (43.0) 818 (40.4) 776 (40.6) 506 (35.6) 77,087 (40.9) 
No (%) that identify as black race 17,991 (4.7) 9,826 (5.1) 390 (7.3) 133 (6.6) 137 (7.2) 120 (8.5) 7,775 (4.1) 
No (%) as "Ever Smoker" 
144,628 
(37.6) 78,931 (41.4) 2,515 (46.9) 987 (48.7) 885 (46.3) 643 (45.3) 63,182 (33.5) 
No (%) with CKD by eGFR, 
ml/min/1.73m2               
  eGFR >=60 
169,005 
(85.1) 
110,537 
(82.2) 3,032 (56.6) 1,079 (57.9) 1,085 (63.8) 868 (75.0) 55,436 (93.5) 
  eGFR 45-59 
20,840 
(10.5) 16,892 (12.6) 852 (15.9) 409 (22.0) 291 (17.1) 152 (13.1) 3,096 (5.2) 
  eGFR 30-44 6,585 (3.3) 5,585 (4.2) 483 (9.0) 231 (12.4) 179 (10.5) 73 (6.3) 517 (0.9) 
  eGFR 15-29 1,625 (0.8) 1,246 (0.9) 232 (4.3) 89 (4.8) 107 (6.3) 36 (3.1) 147 (0.2) 
  eGFR <15 492 (0.2) 278 (0.2) 122 (2.3) 55 (3.0) 39 (2.3) 28 (2.4) 92 (0.2) 
No (%) with Diabetes Mellitus 28,574 (7.4) 24,219 (12.7) 1,596 (29.8) 718 (35.5) 587 (30.7) 291 (20.5) 2,759 (1.5) 
No (%) with Hypertension 
89,370 
(23.2) 73,903 (38.7) 3,200 (59.7) 1,340 (66.2) 1,184 (61.9) 676 (47.6) 12,267 (6.5) 
No (%) with Cardiovascular Disease 23,806 (6.2) 19,513 (10.2) 1,357 (25.3) 674 (33.3) 462 (24.2) 221 (15.6) 2,936 (1.6) 
No (%) with Liver Disease 5,236 (1.4) 4,082 (2.1) 299 (5.6) 155 (7.7) 94 (4.9) 50 (3.5) 855 (0.5) 
No (%) with Cancer 10,464 (2.7) 8,131 (4.3) 401 (7.5) 179 (8.8) 150 (7.8) 72 (5.1) 1,932 (1.0) 
Blood Pressure, mean (SD), mmHg               
  Systolic 
120 (110 to 
130) 
122 (112 to 
134) 126 (114 to 138) 
126 (114 to 
138) 
128 (115 to 
140) 
124 (112 to 
137) 
118 (108 to 
126) 
  v 
  Diastolic 
74 (68 to 
80) 75 (68 to 82) 74 (66 to 81) 72 (64 to 80) 74 (66 to 82) 74 (68 to 82) 72 (66 to 80) 
Albumin, median (Q1 to Q3), g/dL 
4.2 (3.9 to 
4.4) 
4.2 (3.9 to 
4.4) 4 (3.7 to 4.3) 4 (3.7 to 4.3) 4 (3.6 to 4.2) 4 (3.7 to 4.3) 4.2 (4 to 4.5) 
Sodium, median (Q1 to Q3), mEq/L 
140 (139 to 
142) 
140 (138 to 
142) 140 (138 to 142) 
140 (138 to 
142) 
140 (138 to 
142) 
140 (138 to 
142) 
140 (139 to 
142) 
No (%) with Proteinuria 21,832 (5.7) 13,976 (7.3) 1,060 (19.8) 476 (23.5) 378 (19.8) 206 (14.5) 6,796 (3.6) 
No (%) Hospitalized 19,362 (5.0) 14,275 (7.5) 1,185 (22.1) 583 (28.8) 393 (20.5) 209 (14.7) 3,902 (2.1) 
No (%) Hospitalized with AKI 811 (0.2) 628 (0.3) 112 (2.1) 72 (3.6) 28 (1.5) 12 (0.8) 71 (0) 
No (%) with Outpatient AKI 5,363 (1.4) 4,147 (2.2) 627 (11.7) 328 (16.2) 198 (10.4) 101 (7.1) 589 (0.3) 
No Cr values during baseline, median 
(Q1 to Q3) 8 (7 to 13) 8 (7 to 13) 10 (7 to 17) 11 (8 to 20) 9 (7 to 16) 9 (7 to 13) 8 (6 to 11) 
Occur During Follow-Up               
No (%) with Death 12,143 (3.2) 9,369 (4.9) 959 (17.9) 424 (20.9) 341 (17.8) 194 (13.7) 1,815 (1.0) 
No (%) Reaching eGFR threshold, 
ml/min/1.73m2               
  eGFR <30 1,744 (0.5) 1,592 (0.8) 152 (2.8) 81 (4.0) 57 (3.0) 14 (1.0) 0 (0) 
  eGFR <45 2,354 (0.6) 2,181 (1.1) 173 (3.2) 94 (4.6) 64 (3.3) 15 (1.1) 0 (0) 
  eGFR <15 713 (0.2) 619 (0.3) 94 (1.8) 41 (2.0) 43 (2.2) 10 (0.7) 0 (0) 
No (%) with eGFR 50% decline 2,551 (0.7) 2,370 (1.2) 181 (3.4) 102 (5.0) 64 (3.3) 15 (1.1) 0 (0) 
No (%) Hospitalized 46,358 (12) 32,941 (17.3) 1,920 (35.9) 776 (38.3) 755 (39.5) 390 (27.5) 11,496 (6.1) 
No (%) Hospitalized with AKI 5,664 (1.5) 4,377 (2.3) 452 (8.4) 229 (11.3) 159 (8.3) 64 (4.5) 835 (0.4) 
No (%) with Recurrent Outpatient 
AKI 14,405 (3.7) 10,632 (5.6) 1,100 (20.5) 409 (20.2) 414 (21.6) 277 (19.5) 2,673 (1.4) 
Last eGFR, median (Q1 to Q3), 
ml/min/1.73m2 
80.8 (68 to 
94.4) 
78.4 (64.9 to 
92.4) 
69.7 (52.0 to 
89.7) 
62.4 (42.4 to 
82.4) 
62.4 (42.2 to 
85.5) 
81.3 (62.1 to 
98.5) 
84.9 (73.7 to 
97.6) 
No (%) with AKI recovery after 
exposure period NA NA NA NA 983 (51.4) 764 (53.8) NA 
Occur at Any Time               
No (%) with Hospital AKI 7,284 (1.9) 5,627 (3.0) 698 (13.0) 370 (18.3) 244 (12.8) 84 (5.9) 959 (0.5) 
No (%) with Outpatient AKI 22,745 (5.9) 14,174 (7.4) 
100% by 
definition 
100% by 
definition 
100% by 
definition 
100% by 
definition 3,213 (1.7) 
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Table 2: Adjusted hazard ratios for various outcomes by AKI group 
Mortality eGFR <30 Hospital AKI Outpatient AKI Hospitalization 
Outcomes by Outpatient AKI Group           
No AKI 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 
AKI with recovery 2.15 (1.91-2.41) 1.73 (1.37-2.19) 2.63 (2.27-2.99) 2.37 (2.14-2.63) 1.76 (1.63-1.89) 
AKI no recovery 1.71 (1.51-1.95) 1.20 (0.91-1.57) 1.94 (1.65-2.27) 2.61 (2.37-2.89) 1.77 (1.65-1.91) 
AKI no repeat Cr 1.77 (1.49-2.12) 0.73 (0.43-1.25) 1.53 (1.20-1.96) 3.40 (3.02-3.83) 1.51 (1.37-1.67) 
No Cr 0.73 (0.68-0.77) NA 0.53 (0.48-0.57) 0.53 (0.50-0.55) 0.67 (0.66-0.69) 
Outcomes by AKI Severity           
No AKI 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 
Stage 1 AKI 1.90 (1.74-2.07) 1.34 (1.10-1.62) 2.06 (1.85-2.30) 2.55 (2.38-2.74) 1.73 (1.64-1.82) 
Stage 2 AKI 1.92 (1.53-2.41) 1.32 (0.86-2.03) 2.21 (1.67-2.92) 3.08 (2.60-3.65) 1.73 (1.51-1.97) 
Stake 3 AKI 2.47 (1.61-3.80) 0.90 (0.37-2.19) 3.25 (2.09-5.06) 2.64 (1.90-3.67) 2.00 (1.58-2.54) 
No Cr 0.73 (0.68-0.77) NA 0.53 (0.49-0.57) 0.53 (0.51-0.56) 0.67 (0.66-0.69) 
Any Outpatient AKI vs. No AKI           
No AKI 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 
Any Outpatient AKI 1.90 (1.76-2.06) 1.33 (1.11-1.59) 2.14 (1.93-2.37) 2.75 (2.57-2.93) 1.71 (1.63-1.79) 
No AKI vs. Outpatient AKI vs. Hospital AKI vs. Both           
No AKI 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 
Outpatient AKI 1.87 (1.72-2.03) 1.37 (1.15-1.65) 2.13 (1.91-2.37) 2.79 (2.61-2.98) 1.70 (1.62-1.78) 
Hospital AKI 2.79 (2.31-3.38) 2.12 (1.30-3.46) 4.30 (3.55-5.21) 2.41 (1.98-2.94) 2.53 (2.26-2.84) 
Outpatient & Hospital AKI 4.42 (3.27-5.96) 1.11 (0.55-2.26) 4.69 (3.58-6.14) 3.00 (2.28-3.96) 2.93 (2.44-3.52) 
1. All are adjusted HR's (Cox model) 
2. Variables in each Cox model included demographics (age, gender, race), baseline comorbidities (diabetes, hypertension, cardiovascular disease, liver 
disease, cancer, smoking status), baseline vitals and labs (last systolic BP, diastolic BP, sodium, albumin, urine protein, and eGFR), baseline events 
(hospitalization, hospital AKI, outpatient AKI), recurrent outpatient AKI during exposure, and total follow-up time 
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Table 3: Adjusted hazard ratios for alternative eGFR thresholds by AKI group 
eGFR <15 eGFR <45 
Primary Analysis     
No AKI 1.0 (Ref) 1.0 (Ref) 
AKI with recovery 1.53 (1.09-2.15) 1.79 (1.44-2.22) 
AKI no recovery 1.40 (1.01-1.96) 1.19 (0.92-1.54) 
AKI no repeat Cr 1.09 (0.58-2.07) 0.63 (0.38-1.06) 
No Cr NA NA 
Any AKI vs. No AKI     
No AKI 1.0 (Ref) 1.0 (Ref) 
Any Outpatient AKI (18mo exp) 1.41 (1.11-1.80) 1.32 (1.13-1.56) 
No AKI vs. Outpatient AKI vs. Hospital AKI vs. Both     
No AKI 1.0 (Ref) 1.0 (Ref) 
Outpatient AKI 1.43 (1.12-1.84) 1.33 (1.12-1.57) 
Hospital AKI 1.09 (0.44-2.69) 2.21 (1.43-3.42) 
Outpatient & Hospital AKI 1.17 (0.55-2.48) 1.77 (0.98-3.17) 
Variables in each Cox model included demographics (age, gender, race), baseline comorbidities (diabetes, hypertension, cardiovascular disease, liver disease, 
cancer, smoking status), baseline vitals and labs (last systolic BP, diastolic BP, sodium, albumin, urine protein, and eGFR), baseline events (hospitalization, 
hospital AKI, outpatient AKI), recurrent outpatient AKI during exposure, and total follow-up time 
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Table 4: Adjusted hazard ratios for primary analysis and all sensitivity analyses 
Mortality eGFR <30 eGFR <15 eGFR <45 
Hospital 
AKI 
Outpatient 
AKI 
Hospitalizati
on 
No AKI (Reference for all analyses below) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 
Primary Analysis               
AKI with recovery 
2.15 (1.91-
2.41) 
1.73 (1.37-
2.19) 
1.53 (1.09-
2.15) 
1.79 (1.44-
2.22) 
2.60 (2.27-
2.99) 
2.37 (2.14-
2.63) 
1.76 (1.63-
1.89) 
AKI no recovery 
1.71 (1.51-
1.95) 
1.20 (0.91-
1.57) 
1.40 (1.01-
1.96) 
1.19 (0.92-
1.54) 
1.94 (1.65-
2.27) 
2.61 (2.37-
2.89) 
1.77 (1.65-
1.91) 
AKI no repeat Cr 
1.77 (1.49-
2.12) 
0.73 (0.43-
1.25) 
1.09 (0.58-
2.07) 
0.63 (0.38-
1.06) 
1.53 (1.20-
1.96) 
3.40 (3.02-
3.83) 
1.51 (1.37-
1.67) 
No Cr 
0.73 (0.68-
0.77) NA NA NA 
0.53 (0.48-
0.57) 
0.53 (0.50-
0.55) 
0.67 (0.66-
0.69) 
12 month exposure period               
AKI with recovery 
2.10 (1.82-
2.43) 
1.35 (1.00-
1.82) 
1.02 (0.65-
1.60) 
1.51 (1.15-
1.98) 
2.64 (2.25-
3.10) 
2.01 (1.77-
2.29) 
1.56 (1.43-
1.71) 
AKI no recovery 
1.63 (1.40-
1.91) 
1.26 (0.92-
1.72) 
1.58 (1.09-
2.27) 
1.24 (0.93-
1.67) 
1.89 (1.57-
2.27) 
2.34 (2.09-
2.63) 
1.63 (1.49-
1.77) 
AKI no repeat Cr 
1.22 (0.98-
1.51) 
0.61 (0.35-
1.08) 
0.67 (0.33-
1.37) 
0.51 (0.29-
0.90) 
1.65 (1.30-
2.09) 
3.22 (2.87-
3.61) 
1.40 (1.26-
1.55) 
No Cr 
0.79 (0.75-
0.84) NA NA NA 
0.61 (0.57-
0.65) 
0.62 (0.59-
0.65) 
0.73 (0.71-
0.74) 
24 month exposure period               
AKI with recovery 
2.25 (2.05-
2.48) 
1.90 (1.52-
2.36) 
1.59 (1.15-
2.20) 
2.03 (1.66-
2.46) 
2.71 (2.39-
3.07) 
2.42 (2.20-
2.66) 
1.78 (1.67-
1.90) 
AKI no recovery 
1.78 (1.58-
2.00) 
1.26 (0.96-
1.64) 
1.68 (1.22-
2.31) 
1.16 (0.90-
1.50) 
1.72 (1.47-
2.03) 
2.89 (2.63-
3.17) 
1.82 (1.70-
1.95) 
AKI no repeat Cr 
1.79 (1.51-
2.13) 
1.13 (0.71-
1.80) 
1.87 (1.11-
3.15) 
0.97 (0.62-
1.5) 
1.77 (1.39-
2.24) 
3.57 (3.17-
4.03) 
1.46 (1.32-
1.62) 
No Cr 
0.68 (0.63-
0.73) NA NA NA 
0.50 (0.45-
0.54) 
0.48 (0.45-
0.51) 
0.64 (0.62-
0.66) 
No Cr Group Excluded               
AKI with recovery 
2.14 (1.91-
2.4) 
1.73 (1.37-
2.19) 
1.53 (1.09-
2.15) 
1.79 (1.44-
2.22) 
2.61 (2.27-
3.00) 
2.42 (2.19-
2.68) 
1.76 (1.63-
1.89) 
  ix
AKI no recovery 
1.72 (1.51-
1.96) 
1.20 (0.91-
1.57) 
1.40 (1.01-
1.96) 
1.19 (0.92-
1.54) 
1.96 (1.67-
2.30) 
2.70 (2.44-
2.98) 
1.78 (1.65-
1.91) 
AKI no repeat Cr 
1.78 (1.49-
2.12) 
0.73 (0.43-
1.25) 
1.09 (0.58-
2.07) 
0.63 (0.38-
1.06) 
1.55 (1.21-
1.98) 
3.47 (3.08-
3.91) 
1.51 (1.37-
1.67) 
Adjusted for # of Cr values during baseline period               
AKI with recovery 
1.99 (1.68-
2.36) 
1.46 (1.03-
2.06) 
1.38 (0.87-
2.19) 
1.57 (1.14-
2.16) 
2.32 (1.93-
2.80) 
2.21 (1.89-
2.59) 
1.59 (1.42-
1.78) 
AKI no recovery 
1.38 (1.07-
1.77) 
0.99 (0.62-
1.61) 
0.79 (0.42-
1.49) 
1.01 (0.64-
1.59) 
1.43 (1.08-
1.89) 
1.97 (1.61-
2.43) 
1.33 (1.14-
1.55) 
AKI no repeat Cr 
1.99 (1.43-
2.78) 
0.35 (0.09-
1.42) 
0.50 (0.12-
2.03) 
0.31 (0.08-
1.26) 
1.72 (1.11-
2.69) 
1.96 (1.38-
2.77) 
1.26 (0.98-
1.62) 
No Cr 
0.68 (0.53-
0.87) NA NA NA 
0.46 (0.34-
0.63) 
0.70 (0.57-
0.87) 
0.62 (0.55-
0.69) 
Follow-up began with the last Cr value during exposure 
period               
AKI with recovery   
1.76 (1.39-
2.23) 
1.56 (1.11-
2.18) 
1.83 (1.47-
2.27)       
AKI no recovery   
1.21 (0.92-
1.59) 
1.40 (1.01-
1.96) 
1.20 (0.93-
1.55)       
AKI no repeat Cr   
0.75 (0.44-
1.28) 
1.12 (0.59-
2.12) 
0.64 (0.39-
1.07)       
No Cr   NA NA NA       
Last Cr value used to censor rather than any data point 
in the EHR               
AKI with recovery   
1.90 (1.51-
2.40) 
1.69 (1.21-
2.37) 
1.94 (1.56-
2.40)       
AKI no recovery   
1.25 (0.95-
1.64) 
1.42 (1.01-
1.98) 
1.24 (0.96-
1.60)       
AKI no repeat Cr   
0.73 (0.43-
1.23) 
1.06 (0.56-
2.02) 
0.63 (0.38-
1.05)       
 1. Variables in each Cox model included demographics (age, gender, race), baseline comorbidities (diabetes, hypertension, cardiovascular disease, liver disease, 
cancer, smoking status), baseline vitals and labs (last systolic BP, diastolic BP, sodium, albumin, urine protein, and eGFR), baseline events (hospitalization, 
hospital AKI, outpatient AKI), recurrent outpatient AKI during exposure, and total follow-up time 
2. Time dependent Cox model includes the same variables with the exception of recurrent outpatient AKI during exposure and total follow-up 
 
  x 
Table 5: Post-hoc analyses including a time dependent analysis and sensitivity analysis excluding misclassified patients 
Mortality eGFR <30 
Time Dependent Cox Model     
Cr measured (n=147,821) 0.87 (0.79-0.95)   
Outpatient AKI (n=11,132) 1.55 (1.28-1.88)   
Repeat Cr after outpatient AKI (n=7,393) 0.55 (0.41-0.74)   
Recovery of AKI (n=3,496) 1.19 (0.87-1.63)   
      
Excluding patients with AKI that recover after exposure period     
No AKI 1.0 (Ref) 1.0 (Ref) 
AKI with recovery 2.10 (1.85-2.37) 1.57 (1.21-2.04) 
AKI no recovery 2.08 (1.64-2.63) 2.16 (1.49-3.14) 
AKI no repeat Cr 3.66 (2.54-5.27) 1.19 (0.38-3.71) 
No Cr 0.72 (0.67-0.77) NA 
1. Variables in all Cox models included demographics (age, gender, race), baseline comorbidities (diabetes, hypertension, cardiovascular disease, liver disease, 
cancer, smoking status), baseline vitals and labs (last systolic BP, diastolic BP, sodium, albumin, urine protein, and eGFR), baseline events (hospitalization, 
hospital AKI, outpatient AKI), recurrent outpatient AKI during exposure, and total follow-up time 
2. Time dependent Cox model includes the same variables with the exception of recurrent outpatient AKI during exposure and total follow-up 
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AKI by Setting Definition 
Outpatient AKI 
AKI diagnosed and managed in the outpatient setting without hospital 
admission within 7 days after AKI detected 
Community-acquired AKI 
AKI resulting in hospital admission within 7 days or present on day of 
admission 
Hospital-acquired AKI 
AKI occurring during hospital hospitalization, but not present on day of 
admission 
Hospital AKI Community-acquired and hospital-acquired AKI combined 
    
AKI and Recovery 
Definitions   
AKI 
A 50% rise in Cr with a moving baseline using an average of the last three Cr 
values 7-365 days prior for outpatient AKI and 30-365 days for hospital AKI 
Recovery from AKI Recovery of the Cr to within 110% of the baseline Cr after AKI 
    
AKI Severity (Modified 
KDIGO Classification)   
Stage 1 Rise in Cr of 1.5-1.9 times the baseline Cr 
Stage 2 Rise in Cr of 2.0-2.9 times the baseline Cr 
Stage 3 Rise in Cr at least 3.0 times the baseline Cr 
    
AKI Groups in our 
Cohort   
No AKI 
At least one Cr value present during the 18 month exposure period with no 
AKI occurring during this time period 
AKI with recovery 
AKI and a future Cr value during the exposure period meeting criteria for 
recovery as defined above  
AKI without recovery 
AKI and a future Cr value during the exposure period not meeting criteria for 
recovery 
AKI without repeat Cr 
AKI without a repeat Cr value during the exposure period to assess for 
recovery 
No Cr No Cr value available during the exposure period 
    
Proteinuria 
Classification (Adapted 
from KDIGO)   
0 
Urine dipstick 0 or trace or urine albumin:creatinine or protein:creatinine <30 
mg/g or 24 hour urine protein <30 mg 
1 
Urine dipstick 30-100 mg/dl or urine albumin:creatinine or protein:creatinine 
30-299 mg/g or 24 hour urine protein 30-299 mg 
2 
Urine dipstick 300+ mg/dl or urine albumin:creatinine or protein:creatinine 
>300 mg/g or 24 hour urine protein >300 mg 
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Introduction 
Chronic kidney disease (CKD) is a growing problem around the world. It is a disease that 
is becoming more prevalent in the United States as our population ages and as it becomes 
more commonplace to live with multiple co-morbidities.1 Individuals with CKD have 
shorter lifespan, increased morbidity, and are particularly at risk for cardiovascular 
events.1 The final stage of CKD (end stage renal disease) requires renal replacement 
therapy for patients to survive, which currently is in the form of either dialysis or a 
kidney transplant. Given the limited number of available organs for kidney 
transplantation, there has been a progressive rise in the number of patients in the United 
States on dialysis.1 Unfortunately, the morbidity and mortality of patients on dialysis is 
high, often being compared to having a diagnosis of cancer. The median life expectancy 
for patients on dialysis is less than five years and the physical, mental, and emotional 
burden limits quality of life for many.1  
 
One potential cause of chronic kidney disease is acute kidney injury (AKI), which refers 
to a relatively sudden loss of kidney function that may or may not recover. While AKI 
definitions vary, most of these definitions rely upon measurement of serum creatinine 
(Cr) values. A common guideline used to define AKI is the Kidney Disease Improving 
Global Outcomes (KDIGO) classification, which requires a rise in serum Cr of at least 
0.3 mg/dL within 48 hours or a rise in serum Cr at least 1.5 times the patient’s baseline 
serum Cr within seven days.2 The KDIGO definition of AKI also allows a diagnosis 
based on low urine output as it was designed for use in the hospital where measurement 
of urine output is commonplace. So while the KDIGO definition of AKI has its 
limitations in the outpatient setting, including the inability to use urine output to define 
AKI, it remains the most commonly used definition of AKI outside the hospital as well. 
 
AKI has been extensively studied in hospital settings. Incidence rates and risk factors 
have been defined for hospital-acquired AKI3,4 and multiple large observational studies 
have documented its association with CKD, hypertension, hospital length of stay, and 
mortality.3-10 Community-acquired AKI, a term used to describe AKI present on hospital 
admission, is believed to represent about a quarter of AKI events observed in the hospital 
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and the incidence appears to be rising.11,12 Community-acquired AKI, like hospital-
acquired AKI, is associated with a higher incidence of CKD and mortality,13,14 though 
studies are conflicting on which has a higher risk.12,15  
 
Contrary to hospital AKI, little is known about AKI in the outpatient setting that does not 
require hospital admission.  Outpatient AKI is witnessed and managed primarily by 
primary care physicians rather than hospitalists and intensivists, but the incidence and 
burden of disease remains unknown in this setting. The few studies that have addressed 
this issue have found that outpatient AKI may be common and associated with increased 
mortality and CKD.12,16-19 However, there has been no comprehensive study analyzing 
patients with and without outpatient AKI and there has been no studies at all looking at 
outpatient AKI in the United States. Further, no study has comprehensively compared 
outcomes in patients that recover from outpatient AKI to those that do not recover.  
 
The purpose of this retrospective cohort study was to determine whether outpatient AKI 
is associated with an increased risk of mortality and CKD with a focus on how recovery 
and severity of AKI impact these associations. Secondary outcomes including future 
hospitalization, hospital AKI, and recurrent outpatient AKI will also be analyzed to 
further expand the risk profile of outpatient AKI.  
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Methods 
Data Source 
Patients were identified from the electronic health record (EHR) of Fairview Health 
Services, a large health system in Minnesota that serves the Twin Cities metro area and 
surrounding communities. Fairview is the primary affiliate of the University of 
Minnesota, operates six hospitals and medical centers and more than 40 primary care 
clinics and 55 specialty clinics. The EHR incorporates all inpatient and outpatient 
documentation, labs, imaging, and billing. To capture patient death, the EHR has been 
linked to the Minnesota Death Index. The Institutional Review Board at the University of 
Minnesota approved this study.  
 
Cohort Definition 
The cohort included all adult patients receiving primary care through Fairview Health 
Services (see Figure 1). Those with at least two primary care provider (PCP) visits 
separated by at least 18 months were included. The period between these visits (the 
“baseline period”) was used to establish baseline creatinine (Cr) values, vitals, labs, and 
comorbidities. Patients were excluded if they were less than 18 years old at the second 
qualifying PCP visit. After the baseline period, an 18 month exposure period was used to 
capture outpatient serum Cr values, from which the following subgroups were defined: 
no outpatient AKI (reference group), outpatient AKI with recovery, outpatient AKI 
without recovery, outpatient AKI without a repeat Cr, and no Cr checked during the 
exposure period. AKI events with a hospital admission in the subsequent seven days were 
excluded, as were Cr values obtained in the emergency room. AKI at hospital admission 
or during hospitalization were collected and analyzed separately. Patients who died 
during the exposure period were excluded. Patients with a diagnosis of end stage renal 
disease or with a kidney transplant before the end of the exposure period were also 
excluded. After the 18 month exposure period, a follow-up period began and continued 
until the outcome of interest or a censoring event occurred. Censoring occurred at the 
time of the last data point in the EHR for each patient.  
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AKI was defined as a 50% increase in Cr compared to baseline. Each Cr value had a 
moving baseline that was the average of up to the last three outpatient Cr values 30-365 
days prior (or 7-365 days for hospital AKI).20 If no Cr value was available within 30-365 
days, the most recent Cr value greater than 365 days prior was used as the baseline. 
Recovery from AKI was defined as a return of the Cr to within 10% of the baseline value 
at any time during the exposure period. Severity of outpatient AKI was defined as stage 1 
through 3 based on the KDIGO definition, excluding urine output.2 See table 1 in the 
appendix for all definitions.  
 
Covariate Definitions 
All baseline characteristics were defined using EHR data up to and including the second 
qualifying PCP visit. Baseline characteristics included age, gender, race, and smoking 
status. Baseline comorbidities included diabetes, hypertension, cardiovascular disease, 
liver disease, and any cancer diagnosis. Comorbidities were considered present if at least 
two International Classification of Disease codes for that condition were present during 
the baseline period (see Appendix). Baseline labs and vitals were defined using the last 
value before the end of the baseline period and included blood pressure, estimated 
glomerular filtration rate (eGFR), sodium, albumin, and urine protein. eGFR was 
calculated using the Modification of Diet in Renal Disease [MDRD] equation and urine 
protein was classified as 0, 1, or 2 based on the KDIGO classification.2 (Appendix table 
1) Other covariates included hospitalization, inpatient AKI, and outpatient AKI during 
the baseline period.  
 
Outcome Measures and Definitions 
The principal outcomes were all-cause mortality and renal events (defined as a decrease 
in eGFR to < 30 ml/min/1.73m2 with at least a 50% decline from the last value during the 
exposure period on two measurements). Only outpatient Cr measurements were used to 
assess the renal outcome. Secondary outcomes included hospitalization, hospital AKI, 
and recurrent outpatient AKI. In addition to the primary analysis, each outcome was 
analyzed by severity of AKI and all outpatient AKI groups (with recovery, without 
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recovery, and without a repeat Cr) were combined to compare risk among those with any 
outpatient AKI to those with hospital AKI during the exposure period.  
 
Statistical Analysis 
Baseline variables are reported by AKI group as the mean and standard deviation or 
median and first and third quantiles for continuous variables and as the total number and 
percentage for categorical variables. Principal and secondary outcomes were analyzed as 
time to event with follow-up beginning at the end of the exposure period. The Kaplan-
Meier method and Cox proportional hazard models were used to generate cumulative 
incidence curves and obtain adjusted hazard ratios, adjusting for baseline characteristics, 
comorbidities, vitals, labs, and AKI and hospitalization events that occurred during the 
baseline period. The group without AKI was used as the reference group in all models. 
The models for each outcome included all covariates defined above, which were selected 
a priori. For covariates where data was missing, we considered “NA” to be its own 
unique value and adjusted for this.21,22 We considered a p-value of <0.05 to be 
statistically significant and 95% confidence intervals are provided. R version 3.3.1 was 
used for all statistical analysis (R Foundation for Statistical Computing, Vienna, Austria).   
 
Sensitivity Analyses 
Pre-planned sensitivity analyses included the following: excluding patients without a Cr 
during the exposure period, adjusting for the number of Cr values measured during 
baseline, changing the exposure period from 18 months to 12 and 24 months, changing 
the exposure period to end at the date of the last Cr measurement, censoring by using the 
date of the last Cr measurement during follow-up, and utilizing two alternative eGFR 
thresholds for the renal outcome (< 45 and < 15 ml/min/1.73m2). A post-hoc time-
dependent Cox model that otherwise mirrored the primary analysis was conducted with 
follow-up starting at the second qualifying PCP visit and hazard ratios determined for the 
following (with the reference as no event): Cr measured, outpatient AKI, repeat Cr 
measured after outpatient AKI, and recovery from outpatient AKI. A post-hoc sensitivity 
analysis excluding patients that recovered from AKI after the exposure period was also 
conducted.  
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Results 
Cohort Characteristics 
There were 1.77 million patients identified from the EHR, of which 384,869 were 
included in our cohort (Figure 2). Of these, nearly equal numbers of patients had no Cr 
measured during the exposure period (49.0%) or had at least one Cr measured and did not 
have outpatient AKI (49.6%). Outpatient AKI occurred in 1.4% of patients during the 18 
month exposure period and in 5.9% at any time, which was more common than hospital 
AKI (0.3% and 1.9%, respectively). Compared to patients without outpatient AKI, those 
with AKI were older and more likely to be smokers, female, and black (Table 1). They 
had more comorbidities and were more likely to have had AKI or a hospitalization during 
the baseline period. On average, they had higher systolic blood pressure and more 
proteinuria. Of the 5,358 with outpatient AKI during the exposure period, 37.8% 
recovered, 35.7% did not recover and 26.5% did not have a repeat Cr. More than half 
(52.3%) of the patients in the latter two groups had a Cr qualifying them as recovered 
during follow-up.  
 
Average follow-up was 5.3 years. Overall mortality in the cohort was 3.2%. Mortality 
was lowest in those without a Cr measured (1%), higher in patients without outpatient 
AKI (4.9%), and highest in those with outpatient AKI (17.9%). Patients that recovered 
had the highest mortality (20.9%), followed by those without recovery (17.8%) and those 
without a repeat Cr (13.7%). Renal events occurred during follow-up in 0.8% of patients 
without AKI, and in 4.0%, 3.0%, and 1.0% in patients with outpatient AKI with recovery, 
without recovery, and without a repeat Cr, respectively. Secondary outcomes including 
hospitalization, hospital AKI, and outpatient AKI had a similar pattern among the five 
groups (Table 1).   
 
Outcomes 
Figure 3 shows the unadjusted cumulative incidence curves for mortality, renal events, 
and hospitalization by outpatient AKI group. Table 2 shows the adjusted hazard ratios 
(aHR’s) for the principal and secondary outcomes by AKI group and by AKI severity. 
Outpatient AKI was associated with an increased risk for mortality including those with 
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recovery (aHR 2.15, 95% CI 1.91-2.41), with no recovery (aHR 1.71, 95% CI 1.51-1.95), 
and with no repeat Cr (aHR 1.77, 95% CI 1.49-2.12). In a post-hoc time dependent 
analysis, the association between outpatient AKI and mortality was consistent (aHR 1.55, 
CI 1.28-1.88). Measurement of Cr after outpatient AKI was associated with lower 
mortality (aHR 0.55, CI 0.41-0.74), but having a repeat Cr qualifying as recovery was not 
associated with a further reduction in mortality (aHR 1.19, CI 0.87-1.63).  
 
Outpatient AKI with recovery was associated with an increased risk for the principal 
renal outcome (aHR 1.73, 95% CI 1.37-2.19), but the AKI without recovery and AKI 
with no repeat Cr groups were not at increased risk for renal events in the primary 
analysis (aHR 1.20, CI 0.91-1.57, aHR 0.73, CI 0.43-1.25, respectively). When those that 
recovered from outpatient AKI after the exposure period were excluded in post-hoc 
analyses (Appendix Table 4), there was an increased risk of the renal outcome in the AKI 
without recovery group (aHR 2.16, 95% CI 1.49-3.14) as well as the AKI with recovery 
group (aHR 1.57, 95% CI 1.21-2.04).  
 
All categories of outpatient AKI were associated with increased risk for secondary 
outcomes of hospital AKI, outpatient AKI, and hospitalization (Table 2). Additionally, in 
secondary analyses, each stage of outpatient AKI was associated with an increased risk of 
mortality. Stage 1 outpatient AKI was associated with increased risk for renal events 
(aHR 1.34, CI 1.10-1.62) while stage 2 and 3 were not (aHR 1.32, CI 0.86-2.03, aHR 
0.90, CI 0.37-2.19). Each stage of outpatient AKI was associated with an increased risk 
for hospitalization, inpatient AKI, and recurrent outpatient AKI. Hospital AKI was 
associated with an increased risk for mortality (aHR 2.79, 95% CI 2.31-3.38), renal 
events (aHR 2.12, 95% CI 1.30-3.46), and all secondary outcomes. The highest risk of 
mortality occurred in those with hospital and outpatient AKI (aHR 4.42, 95% CI 3.27-
5.96). Similar results were observed for renal events and secondary outcomes. 
 
Sensitivity Analyses 
Sensitivity analyses are shown in the Appendix. Shortening the exposure period from 18 
months to 12 months tended to attenuate the aHR slightly for each outcome in each AKI 
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group and lengthening it to 24 months tended to increase the aHR slightly, without 
changing the direction or statistical significance. One exception was the 95% confidence 
interval for mortality in the AKI with no repeat Cr group, which only crossed 1.0 in the 
12-month exposure group. Results were consistent in sensitivity analyses for principal 
and secondary outcomes when excluding those without a Cr checked during the exposure 
period and when adjusting for the number of Cr measurements during the baseline period. 
For the renal outcome, results were consistent regardless of the eGFR threshold or 
whether the last Cr during the exposure period or last Cr during follow-up was used to 
start and end follow-up, respectively.  
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Discussion 
In the most comprehensive study of its kind, we observed that outpatient AKI not 
requiring hospital admission is more than three times as common as AKI observed in the 
hospital and is an independent risk factor for incident CKD and mortality even among 
patients who recover to within 10% of their baseline Cr. Compared to patients with no 
AKI, those with outpatient AKI had a 33% increased risk of renal events and a 90% 
increase in mortality. Recovery from outpatient AKI was not protective from this 
increased risk for mortality in either the primary analysis or in a time dependent analysis. 
Further, outpatient AKI more than doubled the risk of future outpatient and hospital AKI 
events and increased the risk of future hospitalization by more than 50%. 
 
Five retrospective studies have analyzed outcomes after outpatient AKI. Four of these 
studies were conducted in the United Kingdom (UK) and one in Canada with a variety of 
sampling methods, definitions, and outcomes. The first was limited to patients with 
advanced CKD and found those with outpatient AKI had greater than double the risk for 
dialysis initiation and death compared to age and gender matched controls.18 Two 
subsequent registry cohorts from a single center and single county in the UK also found 
increased risk of mortality in patients with outpatient AKI with increased risk regardless 
of severity.16,19 A larger cohort from a UK health authority registry divided patients into 
groups with hospital-acquired, community-acquired, and outpatient AKI. They found that 
five-year mortality was high in all three (67.1%, 64.7%, and 46.2%, respectively).12 
However, there were no patients without AKI in the adjusted model for this cohort. Most 
recently, in a cohort study from Wales, mortality was 25% overall for those with AKI and 
was higher with hospital AKI and with increasing severity. Hospital-acquired AKI was 
least likely to recover and AKI detected in the community was more likely to lead to 
worsening renal function at 90 days.17 These prior studies are limited by a lack of control 
group without AKI12,17 and an inability to adjust for important comorbidities.17-19 
 
Our study is the most comprehensive analysis of outpatient AKI and is the first American 
cohort. Strengths are its size, length of follow-up, robust comparator arm, and 
comprehensive clinical data allowing for adjustment of potential confounders and 
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assessment of multiple important outcomes. Consistent results in multiple sensitivity 
analyses also increase confidence in the results. Outpatient AKI was a risk factor for 
every outcome analyzed. Outpatient AKI had nearly double the risk of mortality over 5 
years compared to patients without outpatient AKI with an incidence more than three 
times that of hospital AKI. Similar to prior studies that have shown hospital AKI to be a 
risk factor for mortality and CKD regardless of severity or whether the Cr returns to 
baseline,5,7,9 we found that even the mildest form of outpatient AKI (1.5-1.9x the baseline 
Cr) and those that recover their Cr to baseline have a significantly increased risk of 
mortality, CKD, hospitalization, and recurrent AKI.  
 
There are several limitations to our study. First, this is a retrospective observational 
cohort with all the inherent limitations including differential follow-up. We attempt to 
account for this by adjusting for possible confounders including demographics, vital 
signs, labs, and comorbidities. Second, this is a single health system database in a metro 
area with multiple health systems. This problem is limited given the size and expansive 
nature of the health system and by selecting patients who received their primary care 
within the system. Third, while limited mostly to lab tests in our database, there is 
missing data. We account for this by using “missingness” as a variable to adjust for rather 
than by imputation, which is limited by an assumption of randomness. Fourth, there are 
no established uniform definitions for outpatient AKI like those for hospital AKI. 
Knowing this limitation, we chose to use a 50% rise in Cr to define outpatient AKI 
because it remains a significant change in eGFR regardless of the baseline Cr. Finally, we 
chose to utilize an exposure period of 18 months, which is an effective method to define 
comparator groups, but is an arbitrary period of time and may result in survivorship bias 
and misclassification. We accounted for this by using two alternative exposure period 
lengths (12 and 24 months) and by conducting a time-dependent analysis, neither of 
which changed the overall conclusions.  
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Conclusions and Future Directions 
In summary, outpatient AKI was common and occurred more than three times as often as 
hospital AKI in our cohort. Outpatient AKI was associated with an increased risk of 
death and renal events as well as hospitalization, hospital AKI, and recurrent outpatient 
AKI even in those in whom Cr recovered to within 10% of baseline. Further research is 
necessary to better understand the etiology and pathophysiology underlying outpatient 
AKI in order to develop approaches to prevent AKI events as well as reduce risk for the 
subsequent adverse outcomes. 
 
Future research efforts surrounding outpatient AKI should now focus on prevention, early 
detection, and rapid intervention. Unfortunately, evidence on how and where to focus 
these efforts is limited. A conceptual model was created to help visualize the scope of this 
research and define future research needs (Figure 4). While this research provides strong 
evidence of the burden of outpatient AKI, the conceptual model emphasizes the 
uninvestigated areas and refocuses the eye on the bigger picture. 
 
If the ultimate goal is to learn something about how to positively impact the health of 
individuals and populations, attention must be directed to identifying risk factors and 
determining how environment and health care delivery impact AKI and outcomes. It may 
be straight forward to identify risk factors such as demographics and comorbidities, but it 
is also necessary to understand the role of patient behavior and genetic predisposition. 
Meanwhile, investigation of the pathophysiology and mechanisms between risk factors, 
outpatient AKI, and outcomes should be simultaneous and complimentary.  
 
While I intend to continue to tap the vast amount of data in the electronic health record to 
further investigate risk factors, modifiers, and outcomes of outpatient AKI, a more 
comprehensive understanding will require a more diverse range of research. It will 
require retrospective, prospective, bench, and translational research and participation 
from individuals ranging from those pipetting at the bench to those caring for patients in 
clinic. The findings of this thesis project document the importance of outpatient AKI and 
the potential to reduce the significant burden it leaves in its wake. 
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